NEW YORK (GenomeWeb News) – Cancer genetics diagnostic company NeoGenomics today reported flat revenues for the second quarter, as changes to Medicare's reimbursement for molecular diagnostics negatively impacted operations.

The Fort Myers, Fla.-based company said that revenues for the three months ended June 30 totaled $15.6 million, the same as a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.